Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
COLUMBIA, Md., May 31, 2017 -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30th, 2017, appointed Mr. David White as a director, upon recommendation of the Nominating Committee. The Board of Directors also appointed Mr. White as a member of the Audit Committee. Mr. White joins Osiris as an independent Board member and will stand for election at the Company’s 2017 Stockholders Meeting.
“We are pleased to have Mr. White join Osiris at this important time,” said Peter Friedli, Chairman of the Board. “David has extensive and highly relevant business and finance experience, and his contributions will be greatly appreciated.”
Mr. White has more than 25 years of corporate finance and public accounting experience with a track record of achievement in financial management, business and capital allocation strategy, and public company reporting, compliance and governance. Most recently, Mr. White served as Senior Vice President, Chief Financial Officer and Treasurer of Choice Hotels, a New York Stock Exchange listed company, from 2007 until 2016. Prior to joining Choice Hotels in 2002, Mr. White held positions with Ernst & Young, Arthur Andersen and Statoil Energy.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4®, a viable bone matrix, Cartiform®, a viable osteochondral allograft, Grafix®, a cryopreserved placental membrane, and Stravix®, a durable placental allograft. Osiris, Grafix, Cartiform, and Stravix are trademarks of Osiris Therapeutics, Inc. BIO4 is a registered trademark of Howmedica Osteonics Corp. More information can be found on the company's website, www.osiris.com. (OSIR-G)
For additional information, please contact: Diane Savoie Osiris Therapeutics, Inc. (443) 545-1839 [email protected]
